Other Events ·
PolyPid Ltd. held an Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where shareholders…
PYPDPolyPid Ltd.
PolyPid Ltd. held an Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where shareholders approved the re-election of Kost Forer Gabbay & Kasierer as independent auditors, the re-election of eight board members, and amendments to non-executive director option grants and CEO Dikla Czaczkes Akselbrad's option grant. Additionally, the company disclosed that its Board of Directors approved an increase in the 2012 Share Option Plan pool by 1,500,000 ordinary shares, raising the total reserved shares from 3,512,403 to 5,012,403. PolyPid Ltd. is a medical technology company focused on developing products for mucosal tissue repair.